Overview
Antimicrobial resistance (AMR) is a global issue with increasingly severe consequences for the world economy and human health. Vaccines reduce AMR by preventing infectious diseases, but the benefits of vaccination campaigns in improving health and economic outcomes have yet to be extensively quantified. ARVac, a consortium of One Health Trust (founded as CDDEP), Yale, Berkeley, Imperial College London, and Princeton, brings together experts in infectious disease modeling to assess the health and economic benefits of potential, new, and current vaccines targeting pathogens of public health relevance.